Events

Transforming Biopharmaceutical Research with AI at The HESI Annual Meeting 2020.

TUESDAY 9 JUNE | VIRTUAL EVENT

Abstract

The Health and Environmental Sciences Institute (HESI)’s mission is to develop science for a safer, more sustainable world. For HESI’s Annual Meeting 2020, our Executive board director, Jackie Hunter, will take to the virtual stage to demonstrate how AI can be used right at the beginning of the R&D process to improve target identification and validation as well as being used to identify key pathways in disease. Benevolent’s technology platform can be used to better predict the properties of molecules including their safety leading to fewer compounds needing to be physically made. There are still considerable challenges in applying the technology – primarily around access to data, especially negative data and these will be discussed.

 

Prof. Jackie Hunter, BenevolentAI

Professor Jackie Hunter held senior positions at global pharmaceutical organisations including GSK, Proximagen and OI Pharma Partners before joining BenevolentAI as an Executive Board Director in 2016. She brings vast academic and business experience in the biomedical and pharmaceutical sectors. For her services to the pharmaceutical industry, she was awarded a CBE in 2010, Birthday Honours and the 2010 Women of Achievement in Science, Engineering and Technology Award for Discovery, Innovation and Entrepreneurship. She gives the company the insight it needs to operate its unique business model – one which sees it not only researching, but also developing the blueprint for new drugs.

REGISTER >

More Posts

You Might Also Like

Events
New tech brings new hope in our new normal | A Keynote from Joanna Shields at WeAreTechWomen
In this talk, Joanna Shields will demonstrate how human intelligence partnered with technology promises to accelerate new discoveries, new treatments, and new hope for patients.
Jun 26, 2020
Events
Women in Biotech
Peju Oshisanya will join three other exceptional speakers from the biotech industry to discuss their personal journeys through research and biotechnology, also delving into their expertise on AI on how we can adopt this emerging technology to the benefit of biomedical research and how we can avoid the pitfalls.
Jun 4, 2020
Blog
Yoga and mental health: a conversation between two professional scientists and professional yogis
For Mental Health Awareness Week, BenevolentAI’s in-house yogis and bioinformaticians evaluated the scientific research behind the effect of yoga on mental health.
May 20, 2020
News
Potential treatment for COVID-19 identified by BenevolentAI using artificial intelligence enters randomised clinical trial
BenevolentAI announced that baricitinib is entering clinical testing as a potential COVID-19 treatment. Benevolent identified the drug using its AI drug discovery platform. The trial by Eli Lilly will investigate the drug’s efficacy and safety.
Apr 10, 2020
News
Future Fifty: joining forces to drive forward positive change
BenevolentAI today announced it has been selected for Tech Nation’s 2020 Future Fifty cohort. Our CEO Joanna Shields reflects on how joining forces with like-minded industry experts can serve as a powerful vehicle for transformation.
Mar 17, 2020
Video
Challenges of designing an AI platform for Drug Discovery w/ Marek Kultys
Our Senior Product Designer explores the design process at BenevolentAI where he builds user facing tools that help our scientists discover and develop new medicines.
Mar 17, 2020